Runben Biotechnology
603193.SS
Get informed when a big investor buys or sells
+ FollowMarket Cap$8.07B
Close$
$16.44
14.9% downside
Current Fair Value
14.9% downsideOvervalued by 14.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $8.07 Billion |
|---|---|
| Enterprise Value | $7.90 Billion |
| Dividend Yield | $0.46 (2.71%) |
| Earnings per Share | $0.78 |
| Beta | 0.17 |
| Outstanding Shares | 404,593,314 |
Return
| Return on Equity | 15.04% |
|---|---|
| Return on Assets | 13.81% |
| Return on Invested Capital | 16.48% |
Valuation & Multiples
| P/E Ratio | 22.66 |
|---|---|
| PEG | 111.5 |
| Price to Sales | 4.83 |
| Price to Book Ratio | 3.86 |
| Enterprise Value to Revenue | 4.64 |
| Enterprise Value to EBIT | 20.44 |
| Enterprise Value to Net Income | 22 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 20, 2026
EPS Estimate
$0.43
Average shareholder expectationRevenue Estimate
$787.00 M
Average shareholder expectationNext Earnings Call
Expected Date
October 23, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
$795.27 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Runben Biotechnology
1,018 employees
CEO: Guiqin Zhao Runben Biotechnology Co., Ltd. focuses on the creation, production, and distribution of mosquito repellent solutions, infant care items, and essential oil products. The company primarily sells its offerings through digital sales channels...